These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 24551084)
61. Improving furosemide polymorphs properties through supramolecular complexes of β-cyclodextrin. Garnero C; Chattah AK; Longhi M J Pharm Biomed Anal; 2014 Jul; 95():139-45. PubMed ID: 24667568 [TBL] [Abstract][Full Text] [Related]
62. Interaction of omeprazole with a methylated derivative of beta-cyclodextrin: phase solubility, NMR spectroscopy and molecular simulation. Figueiras A; Sarraguça JM; Carvalho RA; Pais AA; Veiga FJ Pharm Res; 2007 Feb; 24(2):377-89. PubMed ID: 17177111 [TBL] [Abstract][Full Text] [Related]
63. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes. Patel SG; Rajput SJ AAPS PharmSciTech; 2009; 10(2):660-9. PubMed ID: 19459053 [TBL] [Abstract][Full Text] [Related]
64. Diclofenac-beta-cyclodextrin binary systems: physicochemical characterization and in vitro dissolution and diffusion studies. Manca ML; Zaru M; Ennas G; Valenti D; Sinico C; Loy G; Fadda AM AAPS PharmSciTech; 2005 Oct; 6(3):E464-72. PubMed ID: 16354006 [TBL] [Abstract][Full Text] [Related]
65. Comparative analysis of zaleplon complexation with cyclodextrins and hydrophilic polymers in solution and in solid state. Jablan J; Szalontai G; Jug M J Pharm Biomed Anal; 2012 Dec; 71():35-44. PubMed ID: 22898722 [TBL] [Abstract][Full Text] [Related]
66. Ternary complexation of carvedilol, beta-cyclodextrin and citric acid for mouth-dissolving tablet formulation. Pokharkar V; Khanna A; Venkatpurwar V; Dhar S; Mandpe L Acta Pharm; 2009 Jun; 59(2):121-32. PubMed ID: 19564138 [TBL] [Abstract][Full Text] [Related]
67. [Physical and chemical characterization of allantoin-beta-cyclodextrin inclusion complex]. Gafiţanu C; Popescu C; Singurel G; Macocinschi D Rev Med Chir Soc Med Nat Iasi; 2004; 108(1):173-6. PubMed ID: 15688779 [TBL] [Abstract][Full Text] [Related]
68. Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics. Madan J; Dhiman N; Parmar VK; Sardana S; Bharatam PV; Aneja R; Chandra R; Katyal A Cancer Chemother Pharmacol; 2010 Feb; 65(3):537-48. PubMed ID: 19597818 [TBL] [Abstract][Full Text] [Related]
69. Characterization of an inclusion complex of ethyl benzoate with hydroxypropyl-β-cyclodextrin. Yuan C; Lu Z; Jin Z Food Chem; 2014; 152():140-5. PubMed ID: 24444918 [TBL] [Abstract][Full Text] [Related]
70. Solubility and dissolution rate of progesterone-cyclodextrin-polymer systems. Lahiani-Skiba M; Barbot C; Bounoure F; Joudieh S; Skiba M Drug Dev Ind Pharm; 2006 Oct; 32(9):1043-58. PubMed ID: 17012117 [TBL] [Abstract][Full Text] [Related]
71. In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-beta-cyclodextrin. Nie S; Fan X; Peng Y; Yang X; Wang C; Pan W Arch Pharm Res; 2007 Aug; 30(8):991-1001. PubMed ID: 17879753 [TBL] [Abstract][Full Text] [Related]
73. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin. Liu M; Cao W; Sun Y; He Z Int J Pharm; 2014 Dec; 477(1-2):159-66. PubMed ID: 25455768 [TBL] [Abstract][Full Text] [Related]
74. Solid-state characterization and dissolution properties of bicalutamide-beta-cyclodextrin inclusion complex. Patil AL; Pore YV; Kuchekar BS; Late SG Pharmazie; 2008 Apr; 63(4):282-5. PubMed ID: 18468387 [TBL] [Abstract][Full Text] [Related]
75. Formulation and in vivo evaluation of orally disintegrating tablets of clozapine/hydroxypropyl-β-cyclodextrin inclusion complexes. Zeng F; Wang L; Zhang W; Shi K; Zong L AAPS PharmSciTech; 2013 Jun; 14(2):854-60. PubMed ID: 23649995 [TBL] [Abstract][Full Text] [Related]
76. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129 [TBL] [Abstract][Full Text] [Related]
77. Preparation, characterization and biological evaluation of β-cyclodextrin-biotin conjugate based podophyllotoxin complex. Zhao X; Qiu N; Ma Y; Liu J; An L; Zhang T; Li Z; Han X; Chen L Eur J Pharm Sci; 2021 May; 160():105745. PubMed ID: 33549707 [TBL] [Abstract][Full Text] [Related]
78. Development of carvedilol-cyclodextrin inclusion complexes using fluid-bed granulation: a novel solid-state complexation alternative with technological advantages. Alonso EC; Riccomini K; Silva LA; Galter D; Lima EM; Durig T; Taveira SF; Martins FT; Cunha-Filho MS; Marreto RN J Pharm Pharmacol; 2016 Oct; 68(10):1299-309. PubMed ID: 27465985 [TBL] [Abstract][Full Text] [Related]
79. Preparation and characterization of mosapride citrate inclusion complexes with natural and synthetic cyclodextrins. Ali AA; Sayed OM Pharm Dev Technol; 2013; 18(5):1042-50. PubMed ID: 22206481 [TBL] [Abstract][Full Text] [Related]
80. In-vitro dissolution and microbial inhibition studies on anticancer drug etoposide with β-cyclodextrin. Arumugam SP; Balakrishnan SB; Ganesan V; Munisamy M; Kuppu SV; Narayanan V; Baskaralingam V; Jeyachandran S; Thambusamy S Mater Sci Eng C Mater Biol Appl; 2019 Sep; 102():96-105. PubMed ID: 31147064 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]